Sam Brusco, Associate Editor02.07.22
Bladder cancer firm Photocure ASA has earned U.S. Food and Drug Administration (FDA) approval for an improved blue light system for use with the company’s Cysview product in blue light cystoscopy (BLC) procedures to spot non-muscle invasive bladder cancer (NMIBC).
The new system will be manufactured and soon commercialized by KARL STORZ Endoscopy-America, and is approved in the U.S. for procedures needing rigid cystoscopy.
"The successful FDA approval is great news for the bladder cancer community in the U.S.," Geoffrey Coy, VP and GM of North America at Photocure told the press. "In healthcare, constant technical innovation is crucial, and we expect that this new, enhanced BLC system will fulfill our clients' expectations for improving the Blue Light experience. The new system is the next generation and includes practical features to make the technology more user friendly. We look forward to expanding the use of BLC with Cysview."
"At KARL STORZ, we are committed to helping our customers deliver top-quality care, and we believe that our new Blue Light system demonstrates this commitment," said Michael Lyman, Executive Director, Sales & Marketing, Urology and Gynecology, KARL STORZ Endoscopy-America. "The New Blue Light Powered by Saphira will allow us to serve the needs of our customers, providing next-level visualization to enable the right solutions for urological procedures in patients with Non-Muscle Invasive Bladder Cancer and continue our collaboration with the Photocure team to make high-quality BLC available to more patients in the U.S."
The new system will be manufactured and soon commercialized by KARL STORZ Endoscopy-America, and is approved in the U.S. for procedures needing rigid cystoscopy.
"The successful FDA approval is great news for the bladder cancer community in the U.S.," Geoffrey Coy, VP and GM of North America at Photocure told the press. "In healthcare, constant technical innovation is crucial, and we expect that this new, enhanced BLC system will fulfill our clients' expectations for improving the Blue Light experience. The new system is the next generation and includes practical features to make the technology more user friendly. We look forward to expanding the use of BLC with Cysview."
"At KARL STORZ, we are committed to helping our customers deliver top-quality care, and we believe that our new Blue Light system demonstrates this commitment," said Michael Lyman, Executive Director, Sales & Marketing, Urology and Gynecology, KARL STORZ Endoscopy-America. "The New Blue Light Powered by Saphira will allow us to serve the needs of our customers, providing next-level visualization to enable the right solutions for urological procedures in patients with Non-Muscle Invasive Bladder Cancer and continue our collaboration with the Photocure team to make high-quality BLC available to more patients in the U.S."